Navigation Links
MIGENIX Fourth Quarter and Fiscal Year 2008 Financial Results Conference Call & Webcast Notification

Monday, July 21, 2008 - 11:00 a.m. ET; 8:00 a.m. PT

VANCOUVER and SAN DIEGO, CA, July 18 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, will host a conference call and webcast on Monday, July 21, 2008 at 11:00 a.m. ET (8:00 a.m. PT) to discuss financial results for the fourth fiscal quarter and fiscal year ended April 30, 2008 and provide an update on company activities. To participate in the conference call, please dial 416-644-3416 or 1-800-733-7560.

The call will be available for replay until July 28, 2008 by calling 416-640-1917 or 1-877-289-8525 and entering the pass code 21278725 followed by the pound sign. The live and archived webcast can be accessed through the company's website at for the next 90 days.


MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's programs include drug candidates for: the prevention of catheter-related infections (Phase III), the treatment of dermatological diseases (end of Phase II), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis B infections (preclinical). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at

"Jim DeMesa"

James M. DeMesa, M.D.

President & CEO

Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
3. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
4. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
7. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
8. MIGENIX releases CEO message #22
9. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
11. MIGENIX Appoints Pieter Dorsman to Board of Directors
Post Your Comments:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
Breaking Biology News(10 mins):